Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of QLS5133 injection combination therapy in advanced solid tumors
CTR20264190Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS5133 in Nonhematologic neoplasms, clear cell renal cell carcinoma (ccRCC), ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Qilu Pharmaceutical. Started Nov 2026; status: active.
02
Drugs
QLS5133
03
Conditions
Nonhematologic neoplasmsclear cell renal cell carcinoma (ccRCC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20264190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264190.